April 9, 2024

60+ Experts Unite to Author Consensus Statement Championing Duchenne Newborn Screening

Over 60 leading experts in genetics, pediatrics, neurology, and public health advocates have authored a consensus statement in support of implementing Duchenne newborn screening. Key points of the consensus statement include: Timely Intervention: Early screening…

Learn More

March 27, 2024

Fiscal Year 2024 Appropriations Package Signed Into Law, Including Critical Funding for Duchenne and Becker

At the beginning of March, PPMD’s Advocacy Conference brought together more than 120 advocates from 26 different states in Washington, D.C. to advocate on behalf of the Duchenne and Becker community. This past weekend, the…

Learn More

March 19, 2024

PPMD’s 2024 Advocacy Conference Brings Together Community to Support Progress in Fighting for Every Future

Earlier this month, more than 120 PPMD advocates – people with Duchenne and Becker, parents, siblings, grandparents, and other family members and friends – from 26 different states gathered in Washington, D.C. to urge legislators…

Learn More

March 4, 2024

PPMD Hosts Town Hall on Clinical Trials During 2024 Advocacy Conference

The PPMD Town Hall on Clinical Trials, taking place on Monday, March 4th during PPMD’s 2024 Advocacy Conference in Washington, D.C., aims to provide a platform for families affected by Duchenne and Becker to share…

Learn More

March 4, 2024

PPMD Celebrates 30th Anniversary and Three Decades of Progress with Annual Advocacy Conference

Over the past three decades, PPMD has driven Congress to enact legislation that has transformed federal public health, research, therapy development and access policies to bring us closer to ending Duchenne. This advocacy work has resulted…

Learn More

February 27, 2024

Breaking News: Rare Disease Day Congressional Hearing to Address the BENEFIT Act

On Thursday, February 29th, Rare Disease Day, the House Energy and Commerce Committee will hold a congressional hearing, titled “Legislative Proposals to Support Patients with Rare Diseases” at 10:00 am ET. This hearing will review…

Learn More

February 16, 2024

FDA Accepts Efficacy Supplement to Expand ELEVIDYS Indication

PPMD is excited to learn that the U.S. Food and Drug Administration (FDA) has accepted and filed Sarepta Therapeutics’ efficacy supplement to the Biologics License Application (BLA) for ELEVIDYS. The efficacy supplement aims to ​​expand…

Learn More

February 1, 2024

Duchenne Newborn Screening Bill Passes Arizona Senate

Earlier this week, Duchenne parent and PPMD Advocate Jill Castle testified before the Arizona State Senate Health & Human Services Committee in support of Senate Bill 1020, which seeks to add Duchenne to Arizona’s newborn…

Learn More

January 26, 2024

Duchenne Added to Minnesota’s Newborn Screening Panel

PPMD is excited to announce another significant milestone: Minnesota has officially approved the addition of Duchenne to the state’s newborn screening panel! Approximately 63,000 babies are born in Minnesota every year, which means that we…

Learn More

January 25, 2024

CHMP Issues Negative Opinion for Renewal of Conditional Marketing Authorization for Translarna™ (ataluren) in Europe

PPMD is disappointed to learn that the European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) today issued a negative opinion following the re-examination procedure for the conditional marketing authorization of Translarna™…

Learn More